Discontinuing Nebivolol: Critical Safety Guidance
Do not abruptly discontinue nebivolol, especially if you have coronary artery disease—taper the dose over 1-2 weeks to prevent life-threatening complications including myocardial infarction, severe angina exacerbation, and ventricular arrhythmias. 1
Why Abrupt Cessation Is Dangerous
The FDA drug label for nebivolol explicitly warns against sudden discontinuation, particularly in patients with coronary artery disease. 1 The risks include:
- Severe exacerbation of angina pectoris 1
- Myocardial infarction (heart attack), which can occur with or without preceding worsening of angina 1
- Ventricular arrhythmias (life-threatening heart rhythm disturbances) 1
- Rebound hypertension and tachycardia in patients with coronary disease 2
The American College of Cardiology reinforces this warning, emphasizing that abrupt beta-blocker cessation can trigger serious cardiovascular events in patients with ischemic heart disease. 2
Safe Discontinuation Protocol
Tapering schedule: Gradually reduce nebivolol over 1-2 weeks when discontinuation is planned. 1
During the taper:
- Minimize physical activity to reduce cardiac demand 1
- Monitor closely for warning signs: worsening chest pain, shortness of breath, palpitations, or dizziness 1
- If angina worsens or acute coronary insufficiency develops, immediately restart nebivolol (at least temporarily) and seek urgent medical attention 1
Special Populations Requiring Extra Caution
Patients who should never stop abruptly:
- Those with known coronary artery disease 1
- Patients with prior myocardial infarction 2
- Anyone with a history of angina 1
Even patients without overt coronary artery disease should be cautioned against interrupting or abruptly discontinuing therapy, as the FDA label extends this warning beyond just those with known heart disease. 1
Clinical Context: When Beta-Blockers Must Continue
The American College of Cardiology strongly recommends continuing beta-blocker therapy indefinitely in patients with coronary artery disease or prior MI, as these medications reduce mortality and prevent recurrent cardiac events. 2 In these patients, switching to another antihypertensive should involve cross-tapering rather than simple discontinuation.
Perioperative Considerations
If surgery is planned, generally continue nebivolol throughout the perioperative period rather than stopping it, as beta-blocker withdrawal increases the risk of MI and chest pain. 1 If discontinuation is absolutely necessary before major surgery, recognize that the heart's impaired ability to respond to stress may increase surgical risks. 1
Common Pitfall to Avoid
Do not assume nebivolol can be stopped like other medications simply because blood pressure is controlled or side effects occur. The withdrawal syndrome from beta-blockers is a well-documented medical emergency that can occur with any beta-blocker, including nebivolol. 3 Gradual tapering over 7-10 days prevents both symptoms and marked blood pressure elevation. 3
If a discontinuation syndrome develops despite precautions, re-administration of nebivolol is the most appropriate immediate treatment. 3